BR9908088A - Formulação farmacêutica de um composto de didemnin - Google Patents

Formulação farmacêutica de um composto de didemnin

Info

Publication number
BR9908088A
BR9908088A BR9908088-5A BR9908088A BR9908088A BR 9908088 A BR9908088 A BR 9908088A BR 9908088 A BR9908088 A BR 9908088A BR 9908088 A BR9908088 A BR 9908088A
Authority
BR
Brazil
Prior art keywords
didemnin
pharmaceutical formulation
compound
didemnin compound
lyophilized
Prior art date
Application number
BR9908088-5A
Other languages
English (en)
Other versions
BRPI9908088B8 (pt
BR9908088B1 (pt
BRPI9908088C1 (pt
Inventor
Jacob Hendrik Beijnen
Bastiaan Nuyen
Roland Elizabeth Cornel Henrar
Andres Gomez
Jose Jimeno
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10827213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9908088(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BR9908088A publication Critical patent/BR9908088A/pt
Publication of BR9908088B1 publication Critical patent/BR9908088B1/pt
Publication of BRPI9908088B8 publication Critical patent/BRPI9908088B8/pt
Publication of BRPI9908088C1 publication Critical patent/BRPI9908088C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Patente de Invenção: <B>"FORMULAçãO FARMACêUTICA DE UM COMPOSTO DE DIDEMNIN"<D>. Uma composição farmacêutica estável de um composto de didemnin, compreende em primeiro lugar uma preparação de didemnin liofilizada incluindo material solúvel em água e em segundo lugar uma solução de reconstituição de solventes mistos.
BRPI9908088A 1998-02-18 1999-02-18 composição farmacêutica de aplidina e seu método de preparação. BRPI9908088C1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9803448.1A GB9803448D0 (en) 1998-02-18 1998-02-18 Pharmaceutical formulation
PCT/GB1999/000511 WO1999042125A1 (en) 1998-02-18 1999-02-18 Pharmaceutical formulation of a didemnin compound

Publications (4)

Publication Number Publication Date
BR9908088A true BR9908088A (pt) 2000-10-31
BR9908088B1 BR9908088B1 (pt) 2013-05-21
BRPI9908088B8 BRPI9908088B8 (pt) 2017-03-07
BRPI9908088C1 BRPI9908088C1 (pt) 2021-05-25

Family

ID=10827213

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9908088A BRPI9908088C1 (pt) 1998-02-18 1999-02-18 composição farmacêutica de aplidina e seu método de preparação.

Country Status (16)

Country Link
US (1) US8420130B1 (pt)
EP (1) EP1054686B1 (pt)
JP (2) JP4536255B2 (pt)
KR (1) KR100595597B1 (pt)
CN (1) CN1170586C (pt)
AT (1) ATE217532T1 (pt)
AU (1) AU754073B2 (pt)
BR (1) BRPI9908088C1 (pt)
CA (1) CA2321116C (pt)
DE (1) DE69901487T2 (pt)
DK (1) DK1054686T3 (pt)
ES (1) ES2175940T3 (pt)
GB (1) GB9803448D0 (pt)
IL (1) IL137911A (pt)
PT (1) PT1054686E (pt)
WO (1) WO1999042125A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
DE10008128A1 (de) * 2000-02-22 2001-08-23 Bayer Ag Endoparasitizide Mittel
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
HK1054191A1 (zh) 2000-10-12 2003-11-21 Pharma Mar, S.A. 施用aplidine時同時使用myoprotector的癌症治療
HUP0600031A3 (en) * 2000-10-31 2012-02-28 Pharma Mar Kahalalide formulations and their use
RU2292216C2 (ru) * 2000-10-31 2007-01-27 Фарма Мар, С.А. Кахалалид f
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
RU2341283C2 (ru) * 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей
ATE406171T1 (de) * 2003-03-12 2008-09-15 Dana Farber Cancer Inst Inc Aplidine zur behandlung von multiplem myelom
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN100335495C (zh) * 2006-01-23 2007-09-05 南方医科大学 一种海鞘多肽及其制备方法
US8258098B2 (en) 2006-02-28 2012-09-04 Pharma Mar, S.A. Antitumoral treatments
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
DK2672986T3 (da) 2011-02-09 2020-06-08 Glaxosmithkline Llc Frysetørrede formuleringer
US11332480B2 (en) 2017-04-27 2022-05-17 Pharma Mar, S.A. Antitumoral compounds
JP2023517194A (ja) 2020-03-02 2023-04-24 ファルマ、マール、ソシエダード、アノニマ コロナウイルス感染の処置における組合せに使用するためのｐｌｄ
EP4114433A2 (en) 2020-03-02 2023-01-11 Pharma Mar S.A. Compounds for use in viral infections
UY39108A (es) 2020-03-02 2021-09-30 Pharma Mar Sa Compuestos para su uso en el tratamiento de la infección por coronavirus
US20230158104A1 (en) 2020-03-02 2023-05-25 Pharma Mar, S.A. Compounds for use in autoimmune conditions
CN114085272B (zh) * 2022-01-10 2022-06-10 中山大学 一种isaridin类环酯肽衍生物及其制备方法和应用
WO2024165764A1 (en) 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342744A (en) * 1979-07-19 1982-08-03 Lever Brothers Company Hair treatment products
JPS5781413A (en) * 1980-09-12 1982-05-21 Univ Illinois Didemnin antibiotic
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
DE3161556D1 (en) * 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid compositions of gamma interferon
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
ATE220894T1 (de) * 1993-12-29 2002-08-15 Matrix Pharma Zusammensetzung für lokale freigabe von zytostatika
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
JP4172726B2 (ja) 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
ATE208323T1 (de) 1996-07-03 2001-11-15 Paxton C G Ltd Behälter
ES2202644T3 (es) 1996-10-24 2004-04-01 The Board Of Trustees Of The University Of Illinois Sintesis total del analogo hip amino de la didemnin a.
JP2001503746A (ja) 1996-10-24 2001-03-21 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ ジデムニン類似体の半合成法
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
EP0981352B8 (en) * 1997-05-07 2009-06-17 Pharma Mar, S.A. Use of aplidine for the treatment of cardiovascular diseases
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
PT1100589E (pt) 1998-07-30 2005-05-31 Sigma Tau Ind Farmaceuti Utilizacao de propionil-l-carnitina e acetil-l-carnitina na preparacao de medicamentos com actividade anticancerigena
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CA2373643A1 (en) 1999-05-25 2000-11-30 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
KR100518986B1 (ko) 1999-11-15 2005-10-06 파르마 마르, 에스.에이. 아플리딘을 사용하여 암을 치료하는 방법
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
IL152111A0 (en) 2000-04-07 2003-07-31 Univ Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
CA2423462A1 (en) 2000-10-05 2002-04-11 Immunex Corporation Nectin polypeptides, polynucleotides, methods of making and use thereof
AU2001294024C1 (en) 2000-10-12 2006-11-23 Pharma Mar, S.A. Treatment of cancers by aplidine in conjunction with a myoprotector
AU2002224417A1 (en) 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
ES2315404T3 (es) 2001-10-19 2009-04-01 Pharma Mar, S.A. Uso de aplidina para el tratamiento de cancer de pancreas.
RU2341283C2 (ru) 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей

Also Published As

Publication number Publication date
DK1054686T3 (da) 2002-06-17
ATE217532T1 (de) 2002-06-15
EP1054686A1 (en) 2000-11-29
PT1054686E (pt) 2002-09-30
AU2538999A (en) 1999-09-06
JP2010163443A (ja) 2010-07-29
CA2321116C (en) 2009-10-06
BRPI9908088B8 (pt) 2017-03-07
DE69901487T2 (de) 2002-12-19
DE69901487D1 (de) 2002-06-20
US8420130B1 (en) 2013-04-16
WO1999042125A1 (en) 1999-08-26
EP1054686B1 (en) 2002-05-15
CA2321116A1 (en) 1999-08-26
BR9908088B1 (pt) 2013-05-21
CN1170586C (zh) 2004-10-13
BRPI9908088C1 (pt) 2021-05-25
ES2175940T3 (es) 2002-11-16
AU754073B2 (en) 2002-11-07
GB9803448D0 (en) 1998-04-15
JP2002503704A (ja) 2002-02-05
JP4536255B2 (ja) 2010-09-01
KR100595597B1 (ko) 2006-07-03
CN1330551A (zh) 2002-01-09
KR20010040993A (ko) 2001-05-15
IL137911A (en) 2006-04-10
IL137911A0 (en) 2001-10-31
HK1032538A1 (en) 2001-07-27

Similar Documents

Publication Publication Date Title
PT1054686E (pt) Formulacao farmaceutica de um composto de didemnina
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
ATE223232T1 (de) Tocopherolzusammensetzungen zur abgabe von biologisch aktiven substanzen
EE200000225A (et) Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
MY118835A (en) Sustained release compositions and the process for their preparation
NO974618L (no) Farmasöytiske preparater for intranasal administrasjon
EP1100522A4 (en) ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG
TR200002299T2 (tr) Epotilon kompozisyonları.
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
PT1197221E (pt) Preparacoes de g-csf estabilizadas a longo prazo.
YU23302A (sh) Farmaceutski preparati fibrinolitičkog agensa
CA2335551A1 (en) Thyroid hormone analogues and methods for their preparation
AU1307399A (en) Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same
HRP20030050B1 (en) Sustained-release preparations of quinolone antibiotics and method for preparation thereof
ATE247981T1 (de) Proteinenthaltende pharmazeutische zubereitung
DE69906982D1 (de) Ibuprofen und domperidone enthaltende pharmazeutische zusammensetzungen
IT8622105A0 (it) Formulazioni idrosolubili di ubidecarenoni, procedimento per laloro preparazione e composizioni farmaceutiche che li compongono.
HK1026136A (en) Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO DE ARQUIVAMENTO DO PEDIDO POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/02/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 18/02/2019